https://biotechmorning.com/news/biotech-reverse-mergers-shell-company-shortage Biotech Morning en 2026-09-11T14:19:24.075Z Biotech's Hottest Backdoor Into Wall Street Is Running Out of Keys https://biotechmorning.com/news/kailera-obesity-pill-side-effects Biotech Morning en 2026-09-11T14:18:38.657Z Kailera's Obesity Pill Works. The Side Effects? Yikes. https://biotechmorning.com/news/car-t-prevention-multiple-myeloma Biotech Morning en 2026-09-11T14:17:56.491Z What If You Could Kill Cancer Before It Even Starts? https://biotechmorning.com/news/biohaven-fda-hold-after-350m-deal Biotech Morning en 2026-09-11T14:17:07.572Z Biohaven Signed a $350M Deal. Nine Days Later, the FDA Called. https://biotechmorning.com/news/kura-oncology-diabetes-spinout-caspian-therapeutics Biotech Morning en 2026-09-11T14:16:21.503Z An Oncology Company Just Launched a Diabetes Startup. Wait, What? https://biotechmorning.com/news/abbvie-menstrual-migraine-atogepant-phase-3 Biotech Morning en 2026-09-11T14:15:32.787Z AbbVie Just Found a $6 Billion Problem Nobody Was Solving https://biotechmorning.com/news/andy-plump-takeda-rd-retirement Biotech Morning en 2026-09-11T14:14:46.530Z The Man Who Taught Big Pharma to Date Startups Is Leaving https://biotechmorning.com/news/frazier-life-sciences-1-1-billion-fund-close Biotech Morning en 2026-09-11T14:14:03.723Z Biotech's Funding Winter Has a $1.1 Billion Exception https://biotechmorning.com/news/novartis-shareholder-activist-board-overhaul Biotech Morning en 2026-09-11T14:13:22.790Z Novartis Just Had Its Worst Month in Years. Now Shareholders Want Heads to Roll. https://biotechmorning.com/news/bridgebio-abandons-first-line-kras-lung-cancer Biotech Morning en 2026-09-11T14:12:39.015Z BridgeBio Just Abandoned the Biggest Prize in KRAS Cancer https://biotechmorning.com/news/bms-arlo-cel-car-t-withheld-data Biotech Morning en 2026-09-11T14:11:50.793Z BMS Says Its New CAR-T Worked. It Just Won't Say How Well. https://biotechmorning.com/news/evommune-mrgprx2-eczema-drug-second-phase-2-failure Biotech Morning en 2026-09-10T14:18:52.154Z The Itch Drug That Couldn't Scratch the Surface https://biotechmorning.com/news/novartis-alteogen-subcutaneous-delivery-deal Biotech Morning en 2026-09-10T14:18:05.170Z Novartis Just Bet $3.2 Billion on Killing the IV Drip https://biotechmorning.com/news/first-ai-designed-drug-phase-3-trial Biotech Morning en 2026-09-10T14:17:17.229Z The First AI-Designed Drug Just Reached the Final Boss of Clinical Trials https://biotechmorning.com/news/bayer-sevabertinib-her2-lung-cancer-approval Biotech Morning en 2026-09-10T14:16:33.127Z Bayer Just Crashed the HER2 Lung Cancer Party https://biotechmorning.com/news/samsung-biologics-polypeptide-takeover-peptide-cdmo Biotech Morning en 2026-09-10T14:15:47.110Z Samsung Biologics Just Bet $1.8 Billion on a Single Molecule https://biotechmorning.com/news/mogad-first-approved-treatment-roche-enspryng Biotech Morning en 2026-09-10T14:15:04.709Z The Disease With Zero Approved Treatments Might Finally Get One https://biotechmorning.com/news/roche-simcere-sim0660-preclinical-deal Biotech Morning en 2026-09-10T14:14:18.952Z Roche Just Paid $1.53 Billion for a Drug That's Never Been in a Human https://biotechmorning.com/news/arpa-h-ai-heart-failure-advocate Biotech Morning en 2026-09-10T14:13:28.896Z The Government Wants an AI Doctor for Your Heart https://biotechmorning.com/news/lasker-award-orexin-sleep-scientists-nobel-track Biotech Morning en 2026-09-10T14:12:42.650Z The Sleep Scientists Who Might Be on a Fast Track to Stockholm https://biotechmorning.com/news/novartis-del-desiran-rna-drug-phase-3-failure Biotech Morning en 2026-09-10T14:11:59.487Z Novartis Spent $12 Billion on an RNA Drug. It Just Flopped. https://biotechmorning.com/news/novartis-tourmaline-bio-il6-cardiovascular-deal Biotech Morning en 2026-09-10T14:11:14.954Z Novartis Just Paid $1.4 Billion to Fight Heart Attacks With Inflammation